'Copper drug restores memory and clears toxic Alzheimer's proteins.' Great news, if you're a mouse
A Monash press release says a copper-transport compound restored memory and cleared amyloid. It was a mouse study. The thread's deeper objection isn't the rodents — it's that 35 years of amyloid-clearing drugs have failed in humans.
The compound has already passed safety evaluations for other diseases, which the release frames as a fast path to human trials. The first reply set the tone: 'Great news! If you are a mouse.'
The real reversal is the science underneath. A developer quoted chemist Derek Lowe's verdict that amyloid-directed therapies 'truly, truly do not appear to be the answer' — and a son caring for a parent with the disease explained why amyloid removal hasn't stopped decline.
What the press release claims
Monash University's announcement says a copper-transport drug "restores memory and clears toxic Alzheimer's proteins". The framing the thread fixated on: the compound "has strong potential to quickly transition into human clinics because it has already undergone safety evaluations for other diseases." What the headline omits, and the study makes clear, is that this is a mouse model. The very first reply did the editing the press office wouldn't:
"Great news! If you are a mouse." — a reader trimming the headline
A flagged comment went further, calling it a "nonsense puff piece" whose "restores memory" claim is years of further research away from meaning anything in humans.
The deeper problem: the target itself may be wrong
The most valuable thread didn't stop at "in mice." It questioned whether clearing amyloid does anything at all. A developer caring about the field quoted medicinal chemist Derek Lowe:
"Amyloid-directed therapies truly, truly do not appear to be the answer for Alzheimer's treatment… thirty-five years in which therapy after therapy after therapy aimed at amyloid mechanisms has failed." — Derek Lowe, relayed in the thread
The lived version came from someone watching it up close. A son whose mother has early-onset Alzheimer's described the hard truth: drugs that remove amyloid plaque exist, "as people still decline," because Alzheimer's "is not really a single uniform disease" but a set of subtypes — and a single gene, PSEN1, can guarantee early onset. Another reader linked the decade-old work showing many people without dementia carry plaques in autopsy, "bordering on irresponsible" to keep selling the simple story.
A fairer reading of the work itself
Not everyone wanted to throw out the science with the press release. One commenter drew the line between the two: "people are reacting to the press-release more than the work." Amyloid plaques are real; they "probably don't cause it any more than tombstones cause graveyards" — very related, not necessarily the mechanism. A copper-transport approach might be addressing a real part of the system even if the plaque story is incomplete.
The mouse is not the message
The pattern here is the recurring one in Alzheimer's coverage: a clean mouse result, a university press office that writes "restores memory" without the species, and a public primed by 35 years of amyloid hope. The compound's prior safety data genuinely could speed a trial. But "cleared the protein in mice" and "treats the disease in people" are separated by exactly the graveyard of failed amyloid drugs the thread keeps pointing at.
Get breakdowns like this every day
The top Hacker News stories, unpacked — by email, Telegram, or RSS.
'US battery output breaks records' — until the thread puts China's number next to it
A FRED chart of US battery manufacturing climbing became a record-breaking headline that exists only on HN. Then someone dropped the cell-capacity numbers, and the record looked very different: 70 GWh against China's 1,755.